×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INMB – inmune bio inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INMB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/3
08:39 am
inmb
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) [Yahoo! Finance]
10/31
04:05 pm
inmb
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Medium
Report
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
10/28
08:00 am
inmb
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
Medium
Report
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
10/24
03:08 pm
inmb
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination [Yahoo! Finance]
Low
Report
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination [Yahoo! Finance]
10/24
03:03 pm
inmb
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
Medium
Report
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
10/24
09:30 am
inmb
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
Medium
Report
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
10/24
08:09 am
inmb
Insider Stock Buying Reaches US$951.2k On INmune Bio [Yahoo! Finance]
Low
Report
Insider Stock Buying Reaches US$951.2k On INmune Bio [Yahoo! Finance]
10/21
08:07 am
inmb
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $20.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
04:05 pm
inmb
inmune bio inc. - common stock
MISS
Report
3.2%
inmune bio inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/1
04:24 pm
inmb
Form 8-K Inmune Bio, Inc. For: Oct 31
Low
Report
Form 8-K Inmune Bio, Inc. For: Oct 31
10/31
04:01 pm
inmb
Form 10-Q Inmune Bio, Inc. For: Sep 30
Low
Report
Form 10-Q Inmune Bio, Inc. For: Sep 30
10/28
04:01 pm
inmb
Form 8-K Inmune Bio, Inc. For: Oct 28
Low
Report
Form 8-K Inmune Bio, Inc. For: Oct 28
10/25
04:01 pm
inmb
Form 8-K Inmune Bio, Inc. For: Oct 24
High
Report
Form 8-K Inmune Bio, Inc. For: Oct 24
10/25
10:16 am
inmb
Form SC 13G Inmune Bio, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Medium
Report
Form SC 13G Inmune Bio, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
10/24
04:00 pm
inmb
Form 8-K Inmune Bio, Inc. For: Oct 24
Medium
Report
Form 8-K Inmune Bio, Inc. For: Oct 24
10/11
04:00 pm
inmb
Form 8-K Inmune Bio, Inc. For: Oct 11
Low
Report
Form 8-K Inmune Bio, Inc. For: Oct 11
10/2
04:51 pm
inmb
Form SC 13G/A Inmune Bio, Inc. Filed by: Xencor Inc
Low
Report
Form SC 13G/A Inmune Bio, Inc. Filed by: Xencor Inc
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/11
Form 10-K Inmune Bio, Inc. For: Dec 31
26.3%
4/24 Form 424B3 Inmune Bio, Inc. 20.9%
10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%
10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%
12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%
9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%
8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%
4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%
9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%
8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%
4/24 Form 424B3 Inmune Bio, Inc. 20.9%
10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%
10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%
12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%
9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%
8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%
4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%
9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%
8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%
TOP News Decliners
3/11
INmune Bio Inc. (INMB) CEO R.J. Tesi on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-29.8%
10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%
5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%
8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%
8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%
4/21 Form EFFECT Inmune Bio, Inc. -9.7%
4/3 Form EFFECT Inmune Bio, Inc. -8.3%
8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%
3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%
8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%
10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%
5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%
8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%
8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%
4/21 Form EFFECT Inmune Bio, Inc. -9.7%
4/3 Form EFFECT Inmune Bio, Inc. -8.3%
8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%
3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%
8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: